Maximilian Jenzer

Heidelberg, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

TROPHIT1-a randomized, open-label, multicenter, phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic colorectal cancer patients.

TROPHIT1-a randomized, open-label, multicenter, phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic colorectal cancer patients.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Deep molecular profiling of biliary tract cancer uncovers novel biological mechanisms and therapeutic opportunities.

Deep molecular profiling of biliary tract cancer uncovers novel biological mechanisms and therapeutic opportunities.

Journal: ESMO open

Published: September 16, 2025

Author Correction: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy.

Author Correction: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy.

Journal: Nature cancer

Published: July 15, 2022

Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy.

Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy.

Journal: Nature cancer

Published: December 24, 2021

Interleukin-2 and Interferon-α for Advanced Renal Cell Carcinoma: Patient Outcomes, Sexual Dimorphism of Responses, and Multimodal Treatment Approaches over a 30-Year Period.

Interleukin-2 and Interferon-α for Advanced Renal Cell Carcinoma: Patient Outcomes, Sexual Dimorphism of Responses, and Multimodal Treatment Approaches over a 30-Year Period.

Journal: Urologia internationalis

Published: December 09, 2021

Immuno-oncology gene expression profiling of formalin-fixed and paraffin-embedded clear cell renal cell carcinoma: Performance comparison of the NanoString nCounter technology with targeted RNA sequencing.

Immuno-oncology gene expression profiling of formalin-fixed and paraffin-embedded clear cell renal cell carcinoma: Performance comparison of the NanoString nCounter technology with targeted RNA sequencing.

Journal: Genes, chromosomes & cancer

Published: March 02, 2020

High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer -Results from a prospective pilot study using a 37 gene panel.

High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer -Results from a prospective pilot study using a 37 gene panel.

Journal: Urologic oncology

Published: September 24, 2019

Serum very long-chain fatty acid-containing lipids predict response to immune checkpoint inhibitors in urological cancers.

Serum very long-chain fatty acid-containing lipids predict response to immune checkpoint inhibitors in urological cancers.

Journal: Cancer immunology, immunotherapy : CII

Published: March 23, 2019

The BRCA2 mutation status shapes the immune phenotype of prostate cancer.

The BRCA2 mutation status shapes the immune phenotype of prostate cancer.

Journal: Cancer immunology, immunotherapy : CII

Published: October 30, 2018

Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing disease.

Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing disease.

Journal: Oncotarget

Published: January 16, 2018

Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy.

Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy.

Journal: Urologic oncology

Published: June 29, 2017

Showing 1-11 of 11

Last Updated: 09/26/2026